12/15
02:30 am
gmab
Does Genmab's 2025 Rally Match Its DCF and Earnings Valuation Outlook? [Yahoo! Finance]
Low
Report
Does Genmab's 2025 Rally Match Its DCF and Earnings Valuation Outlook? [Yahoo! Finance]
12/12
02:14 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
12/12
01:52 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]
12/12
01:36 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
12/12
01:35 am
gmab
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Medium
Report
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
12/11
04:24 pm
gmab
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript [Seeking Alpha]
Medium
Report
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript [Seeking Alpha]
12/11
03:18 am
gmab
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting [Yahoo! Finance]
Medium
Report
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting [Yahoo! Finance]
12/10
12:52 pm
gmab
ASH 2025: AbbVie and Genmab's Epkinly sets new standard in second-line FL [Yahoo! Finance]
Low
Report
ASH 2025: AbbVie and Genmab's Epkinly sets new standard in second-line FL [Yahoo! Finance]
12/8
04:30 pm
gmab
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Medium
Report
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
12/7
07:50 am
gmab
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular Lymphoma
Low
Report
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular Lymphoma
12/6
09:30 am
gmab
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Low
Report
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
12/4
06:27 pm
gmab
Assessing Genmab (CPSE:GMAB) Valuation After Its Recent Share Price Strength [Yahoo! Finance]
Low
Report
Assessing Genmab (CPSE:GMAB) Valuation After Its Recent Share Price Strength [Yahoo! Finance]
11/27
07:11 pm
gmab
Genmab (GMAB) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Genmab (GMAB) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/25
09:13 am
gmab
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout [Seeking Alpha]
Low
Report
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout [Seeking Alpha]
11/20
03:51 pm
gmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
Low
Report
Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]
11/19
07:04 pm
gmab
Genmab (CPSE:GMAB) Valuation in Focus After Recent Share Price Pullback [Yahoo! Finance]
Medium
Report
Genmab (CPSE:GMAB) Valuation in Focus After Recent Share Price Pullback [Yahoo! Finance]
11/19
12:55 pm
gmab
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Low
Report
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
11/18
11:34 am
gmab
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma [Seeking Alpha]
Low
Report
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma [Seeking Alpha]
11/18
11:30 am
gmab
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Low
Report
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
11/18
11:30 am
gmab
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Low
Report
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
11/10
11:01 am
gmab
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes [Yahoo! Finance]
Low
Report
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes [Yahoo! Finance]
11/10
08:03 am
gmab
Genmab A/S (NASDAQ:GMAB) had its price target raised by analysts at HC Wainwright from $40.00 to $41.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ:GMAB) had its price target raised by analysts at HC Wainwright from $40.00 to $41.00. They now have a "buy" rating on the stock.
11/10
07:42 am
gmab
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility [Yahoo! Finance]
Low
Report
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility [Yahoo! Finance]
11/8
01:17 pm
gmab
11/8
06:49 am
gmab
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]